key: cord-0773999-2asb7ppu
authors: Stéphanie, Lejeune; Antoine, Deschildre; Rouzic Olivier, Le; Ilka, Engelmann; Rodrigue, Dessein; Muriel, Pichavant; Philippe, Gosset
title: Childhood asthma heterogeneity at the era of precision medicine: Modulating the immune response or the microbiota for the management of asthma attack
date: 2020-05-22
journal: Biochem Pharmacol
DOI: 10.1016/j.bcp.2020.114046
sha: 4f72755f3c5e326fa69beff878a6c98d0dbe4ddd
doc_id: 773999
cord_uid: 2asb7ppu

Exacerbations are a main characteristic of asthma. In childhood, the risk is increasing with severity. Exacerbations are a strong phenotypic marker, particularly of severe and therapy-resistant asthma. These early-life events may influence the evolution and be involved in lung function decline. In children, asthma attacks are facilitated by exposure to allergens and pollutants, but are mainly triggered by microbial agents. Multiple studies have assessed immune responses to viruses, and to a lesser extend bacteria, during asthma exacerbation. Research has identified impairment of innate immune responses in children, related to altered pathogen recognition, interferon release, or anti-viral response. Influence of this host-microbiota dialog on the adaptive immune response may be crucial, leading to the development of biased T helper (Th)2 inflammation. These dynamic interactions may impact the presentations of asthma attacks, and have long-term consequences. The aim of this review is to synthesize studies exploring immune mechanisms impairment against viruses and bacteria promoting asthma attacks in children. The potential influence of the nature of infectious agents and/or preexisting microbiota on the development of exacerbation is also addressed. We then discuss our understanding of how these diverse host-microbiota interactions in children may account for the heterogeneity of endotypes and clinical presentations. Finally, improving the knowledge of the pathophysiological processes induced by infections has led to offer new opportunities for the development of preventive or curative therapeutics for acute asthma. A better definition of asthma endotypes associated with precision medicine might lead to substantial progress in the management of severe childhood asthma.

Up to now, mechanisms explaining susceptibility to develop acute asthma upon respiratory viruses, in particular RV and to a lesser extend RSV, in asthmatic children prone to exacerbation are not fully understood. As innate immune cells play a central role in the onset of anti-viral defenses, they have been the focus of many studies in pediatric and adult asthma, conducted both ex-vivo and in-vivo,

contributing to the identification of new asthma endotypes. The original studies presented in this review have been summarized in Table 1 .

Before addressing the viral infections impact on asthma attacks, we will briefly describe the virus-induced anti-viral responses. Airway epithelial cells (AEC) are the main cellular targets of pathogens, and act as sentinel cells in response to infection (Fig 1) [36] [37] [38] . These structural cells are a central part of innate immune response [39] . They first act as a complex physicochemical barrier, via the presence of tight intercellular junctions and the muco-ciliary escalator, clearing foreign particles out.

If not cleared, Pathogen Associated Molecular Patterns (PAMP) on the surface of infectious agents, will then be recognized through Pattern Recognition Receptors (PRR), in particular Toll-Like Receptors (TLR) and intracellular RNA helicases, which will trigger innate immune responses. Although AEC play an early and central role in orchestrating innate immune defenses, innate immune cells including alveolar macrophages (AM) and dendritic cells (DC), especially plasmacytoid DC (pDC), are also involved in innate immune responses against pathogens [40] [41] [42] [43] [44] .

Studies aiming to explore PRR recognition by epithelial cells and innate immune cells from asthmatic children are multiple but heterogeneous. In cultures of primary AEC from children with severe therapy resistant asthma (STRA), lower expression levels of extracellular and intracellular PRR than healthy controls were observed at baseline [45] . Expression of PRR was also decreased upon infection with RV on these cultures and in those from adult asthmatics, suggesting a persistent defect in adulthood [45, 46] . Hence, in AM from adults with severe asthma, Rupani, et al. also showed a reduction of TLR7 expression after RV infection compared with healthy subjects, with an effect potentially mediated by microRNAs [47] . Conversely, in ex vivo cultures of cells from broncho-alveolar lavages (BAL) cells and peripheral blood mononuclear cells (PBMC) from adults with mild-to-moderate asthma, no impairment of PRR expression (TLR, RNA-helicases) was observed [48] . This discrepancy was also illustrated by our in vivo real-life study conducted in 72 school-age children with allergic asthma hospitalized for severe exacerbation, associated with viral infection in 64% (RV: 51%) [49] . Whereas viral infection did not modulate PRR expression and function on PBMC as compared with non-infected asthmatic patients, a reduced expression of PRR was reported in a sub-group of children prone to reinfection outside an exacerbation (steady state 8 weeks later), and displaying neutrophilic airway inflammation away from exacerbation [10, 49] . Although present both at exacerbation and steady state, this impairment of PRR expression as well as the inflammatory profile was not associated with the clinical evolution and risk of exacerbations in the year following exacerbation [50] .

Altogether, these data suggest that impairment of PRR recognition in asthmatic children could be limited to a subpopulation of patients, potentially severe, and may persist into adulthood. Rather than an altered baseline expression or synthesis of PRR, a down-regulation of the expression and activation of the co-receptors, and/or enzymes involved in signaling may be determinant. Longitudinal in vivo studies could provide more insights into these mechanisms and allow studying their dynamics during the course of the disease.

Activation of PRR on AEC and innate immune cells will onset various signaling pathways, such as interferon regulatory factors (IRF) 3 and 7, and nuclear factor-kappa B pathway (NF-kB). This will lead to the production of anti-viral molecules such as interferons (IFN) and anti-microbial peptides, including interferon-stimulated genes (ISG) as well as cathelicidins and defensins [51] . Anti-microbial peptides have immunomodulatory activities and can alter host cellular responses. LL-37, also called human cationic antimicrobial peptide is the only human peptide of the cathelicidin family and one of the most-studied [52, 53] . In in vitro models, LL-37 has the ability to reduce virus replication, notably for RSV [53, 54] . In a population of 77 asthmatic children, Arikoglu, et al. have shown that children prone to develop acute asthma attacks displayed higher blood levels of cathelicidins and lower levels of vitamin D at baseline than children with controlled asthma, suggesting a role for anti-microbial peptides in acute asthma [55] . However, the evolution of these baseline levels during acute asthma attacks and their impact on the anti-viral and inflammatory response remain unknown.

The majority of studies conducted in asthmatic subjects have had the aim to explore anti-viral IFN response upon viral infection. They have observed a defect of production of type I IFN. In response to RV, most ex-vivo studies have demonstrated an impairment of IFN-α and IFN-β production in AEC from pediatric asthmatic patients compared to levels observed in cells from healthy controls [45, [56] [57] [58] .

This impairment was also demonstrated in adult cells [59] [60] [61] Paramyxoviridae family and well-known potent inductor of IFN-α [62] . They later extended these observations in whole blood cells cultures from adult asthmatics, upon infection with either NDV of RSV [63] . In the later years, similar results have been shown in pediatric studies [64, 65] but also in adult studies [45, 48, 66] . So far, only a few studies have been conducted upon in vivo inoculation and natural infection. In a cohort of preschool children, IFN-α systemic levels were reduced at the time of RVinduced exacerbation in asthmatics, as compared with healthy controls during an asymptomatic RV infection [30] . In our recently published cohort of preschool asthmatic children with natural virus-induced exacerbation (RV: 73%), the most severe children, who were prone-to-exacerbation, displayed lower plasma concentrations of IFN-β at exacerbation than the others, suggesting a defect of production in response to viruses limited to this sub-population [8] . In another study conducted in older children, we did not observe altered IFN responses in sputum, plasma and cultures of stimulated-PBMC of patients presenting a virus-induced exacerbation, compared with those with a non-virus-induced exacerbation [49] . In adult asthmatics, a significant type I IFN defect was demonstrated in bronchial epithelium and sub-epithelium obtained from bronchial biopsies compared with healthy controls, after experimental infection with RV-A16 [67] . In contrast, Schwantes, et al. described elevated rather than low RNA levels of type I IFN in sputum from adult asthmatic patients, compared to those observed in healthy subjects, early in the course of a virus-induced exacerbation. [68] .

Following their discovery in 2003, there has been increasing knowledge regarding the implication of type III IFN implication in anti-viral responses [69] . Ex-vivo studies conducted in AEC from asthmatic subjects have suggested a parallel impairment of IFN-λ1 and IFN-λ2/3 production upon RV infection in pediatric patients [45, 56, 57] , and this impairment seemed to persist in adult patients [46, 59] .

In vivo, this defective response was not observed at the time of asthma exacerbation in sputum and/or PBMC from atopic asthmatic children [30, 49, 70] , nor in adults [68, 71] , suggesting that there are compensatory mechanisms or other sources of IFN, supplementing the defect observed in resident cells.

A few studies have explored the potential pathways leading to a defect of IFN production in asthmatic patients. Downregulation of IRF3 or IRF7, following virus infection in asthmatic cells, has been suggested [57, 59] . Gielen, et al. have also demonstrated a role of the molecule suppressor of cytokine signaling 1 (SOCS1), exercising a negative-feedback on IFN production following viral infection in children with STRA [57] .

Collectively, these studies suggest a potential impairment of anti-viral IFN response, in particular type I IFN, during asthma attack. Rather than explained by immaturity in the first years of life, this defective response could also be limited to a sub-phenotype of patients who are prone-to-exacerbation, from early childhood to adulthood. The effect of age, the kinetics of the IFN response following viral infection and the impact of viral load in the airways remain to be addressed.

Airway epithelial cells display immunoregulatory properties by producing pro-inflammatory cytokines, including alarmins interleukin (IL)-25, IL-33 and thymic stromal lymphopeietin (TSLP), released upon viral infection, and implicated in the recruitment of macrophages, DC, T cells and granulocytes, such as eosinophils and neutrophils. This will promote the adaptive immune response through DC maturation and migration to draining lymph nodes associated with the airways. Dendritic cells will thus induce naïve T cell differentiation into antigen-specific T cells. This will drive the adaptive immune response within the airways to clear the virus out. The alarmins also contribute to a biased T helper (Th)2 immune response by activating type 2 innate lymphoid cells (ILC2) and polarizing DC in order to promote T cells differentiation (Fig 1) . This specific cytokine environment in asthmatic patients favor naïve T cells polarization into Th2 cells, producing IL-4, IL-5, IL-13, as opposed to Th1 cells, producing IFN-γ and TNF-β [37, 72] . These cytokines are responsible for the type 2 inflammation and induce the pathophysiological features of asthma, including eosinophil mobilization, mucus hypersecretion, smooth muscle hyperplasia and airflow obstruction [3, 73] . . Under the influence of IL-5, eosinophils will enter the airways and perpetuate type 2 inflammation [49, 74] . They will also contribute to resolution of immune responses, including tissue repair [75] . Other cytokines, such as type 17

cytokines: IL-17, IL-21, IL-22, can also promote mucus hypersecretion and production of cytokines and chemokines by AEC. They will favor the recruitment of neutrophils, through the induction of C-X-C chemokines, conducting to a state of chronic inflammation [67] . In the longer term, IL-17 may contribute to the development of airway remodeling during asthma by enhancing the production of profibrotic cytokines, proangiogenic factors, proteases and collagen [76, 77] .

In children, the influence of respiratory viruses and innate immune mechanisms on the adaptive immune response development may be crucial. First, some respiratory viruses may induce the release of alarmins, and thus favor the development of Th2 inflammation. A recently published study showed that children with RV-positive-bronchiolitis displayed increased IL-4/IFN- ratio in nasopharyngeal aspirates [78] . Upon RSV infection, Lee, et al. observed a higher production of TSLP by AEC from asthmatic children compared to healthy controls [79] . Hence, some respiratory viruses may induce Th2 inflammation in the airways of children and this may be increased in an asthmatic environment. In a cohort of preschool asthmatic children, ILC markers, such as soluble ST2, were induced in vivo following RV infection in preschool asthmatic children, and were correlated with nasal levels of IL-33 [80] . In our study of school-age children, at exacerbation, airway inflammation in infected patients was characterized by significantly higher IL-5 concentration and eosinophil count than in non-infected patients [49] . This may not be specific to childhood, as Jackson, et al. have also demonstrated an induction of IL-4, IL-5

and IL-13 in BAL following RV inoculation in asthmatic subjects, associated with exacerbation severity [81] . Additional in vitro experiments showed that IL-33 directly induced Th2 cytokine production by T cells and ILC2. However, this RV-inducedTh2 inflammation could be limited to an asthmatic environment in adults, as suggested by an in vitro study reproducing the induction of IL-4 and IL-13 by asthmatic PBMC after co-exposition with RV and IL-33, but showing no effect on PBMC from healthy donors [82] .

In addition, exposure to respiratory viruses has also been associated with an increase in Th17 cytokines, as demonstrated in co-cultures of RSV-infected AEC with T cells [83] .

Interferon production is also closely linked to Th2 and inflammatory cytokines. In asthmatic preschool children prone to exacerbation, we observed simultaneously lower production of Th1 cytokines (IFN-), Th2 cytokines (IL-5), pro-inflammatory cytokines (TNF-α), regulatory cytokines (IL-10), and type 1 IFN (IFN-β) during virus-induced exacerbation in a subgroup of preschool children with characteristics of severe asthma and a history of frequent exacerbations [8] . This association seems to persist in adults, as suggested by Parsons, et al. reporting a parallel decrease of type III IFNs and of IL-6, (C-X-C motif) ligand (CXCL)8 and CXCL10 in adult asthmatic AEC inoculated with RV [46] . In a murine model of allergic asthma, IRF3 controlled the parallel evolution of IFN and Th2 cytokines during acute episodes induced by allergen exposure [84] . Some adult studies have suggested bi-directional influences during viral infection. Upon RV infection, pre-treatment with Th2 cytokines in cultures of AEC may impair TLR3 and IRF3 signaling pathway [59] , or type 1 and 3 IFN expression [57] . Lower production of type I IFN, displayed by some children, could also reduce the apoptosis of neighboredinfected cells and increase viral loads, consequently amplifying airway inflammation, inflammatory cytokine production and thus, asthma attack severity [58, 60] .

Altogether, these studies confirm close interactions between innate and adaptive immune mechanisms against viruses in an asthmatic environment. Modulating airway inflammation, particularly Th2 inflammation, could therefore directly improve anti-viral responses during asthma attacks in some children.

Although the impairment of anti-viral responses plays a key role in asthma attack, characteristics of the microorganisms are also important. First, pathogenicity of RV strongly differs according to subtypes, probably because of the implication of different cellular targets. Indeed, infection with RV-C strains, which use cadherin-related family member 3 (CDHR3) as a receptor, may be associated with higher clinical severity [10, 31, 85] , whereas B serotypes seem to be responsible for milder symptoms.

Interestingly, single nucleotide polymorphism in the CDHR3 gene, which influences the efficiency of RV-C to infect its target cells, has been associated with childhood asthma susceptibility [86] . Moreover, different viral strains could have different replication rates and thus induce higher viral loads [87] .

Rhinovirus C strains could also modulate the airways inflammation, and induce higher levels of Th2 and/or Th17 cytokines, as shown in preschool children with RV-C-induced wheeze [88] . Second, systemic viremia has been observed in children infected with respiratory viruses, such as RV-C, and young age was found to be a risk factor associated with viremia [89] . This state could induce an enhanced inflammation in children by interaction of viruses with systemic immune cells. Finally, viralcoinfection has been frequently observed at exacerbation in asthmatic children, particularly in the preschool years [30, 31] . The combined effects of several viruses within the airways may modulate both the innate and adaptive responses.

These data demonstrate that, in susceptible children, the nature of respiratory viruses, their spreading, as well as their interactions with the host cells may directly impact the inflammation and the severity of asthma exacerbations.

The role of viral carriage and/or asymptomatic infection at steady state, i.e. outside an exacerbation, in asthmatic patients has also been hypothesized. Hence, pediatric studies have shown a frequent virus shedding in children, with RV positive samples observed in 19-29% of unselected asthmatic children and in 15-23% of healthy children [10, 28, 90, 91] . In the previously-cited cohort of preschool children prone to exacerbation, we observed even higher rates, with 67% of positive PCR (51% for RV) at steady state [8] . In 78 school-age children, we also observed that 10% of children had positive RV sampling at exacerbation and steady state, and that RV serotypes were systematically different at both time points, pointing toward reinfection rather than persistence [10] . Consistent with these observations, Bergauer, et al. also found 54% of RV at steady state in preschool children with asthma, vs 45% in healthy controls [30] . Interestingly, RV carriage in both asthmatics and healthy controls was found to be associated with higher levels of type III IFN at baseline than in subjects without.

This increase in baseline inflammation seems to persist in adulthood. Hence, in sputum cells from 57 asthmatic adults, da Silva, et al. have shown higher baseline levels of IFN and anti-viral molecules compared with healthy subjects [92] . In all, one could hypothesize that RV persistence in asthmatic patients could induce a pro-inflammatory state and/or a desensitization of PRR, which could reduce the response against pathogens within the airways upon new infection.

Alongside RV, other respiratory viruses, could also take part in these processes. Metagenomic analyses have made it possible to identify hundreds of viral species within the airways, constituting the respiratory tract virome [93] . In non-asthmatic children, Wang, et al. have shown multiple common epidemic respiratory viruses in children with severe acute respiratory infection, whereas, the virome was less diverse and mainly dominated by the Anelloviridae family in healthy children [94] . Anelloviruses are major components of the virome and display immunomodulatory properties on both innate and adaptive immunity [95] . Although their presence has been associated with an impaired lung function in asthmatic children [96] , to our knowledge, no study has evaluated their association with asthma attacks. Thus, the contribution of these viruses and their interactions with both pathogenic infectious agents, as well as commensal bacteria from the pulmonary microbiota on chronic inflammation and the onset of acute asthma remain to be determined.

Increasing evidence indicates that the respiratory microbiota, including bacterial and viral microorganisms has an important role in respiratory health and disease [97, 98] . In addition, recent data underline the role of bacterial infections in the development and progression of asthma, as summarized in table 2.

During the first weeks of life, the respiratory tract begins to develop a niche-specific community pattern, where Staphylococcus aureus and Corynebacterium replace the originally colonizing bacteria and become the dominant microorganisms [98] . The most dramatic changes occur during the first 2 months. In the following six months, the respiratory microbiota continues to mature; relative abundance of S. aureus declines, and an increase in Moraxella, Streptococcus, Haemophilus, Dolosigranulum, Alloiococcus, and Prevotella sp. is observed. This period is crucial and alterations of the microbiota have been implicated in the development and the manifestations of chronic lung diseases. .

Using bacterial culture techniques, it has been demonstrated that neonates born to asthmatic mothers with upper airway colonization with S. pneumoniae, M. catarrhalis, and/or H. influenzae were at higher risk of presenting asthma at the age of 5 years [32] . This was associated with an aberrant immune response, with increased IL-5 and IL-13 synthesis in PBMC obtained at the age of 6 months [99] . Interestingly, evaluation of the gut microbiota in infants included in the Canadian (CHILD) study showed that infants at risk of asthma exhibited transient alterations of the microbiota, known as dysbiosis, in neonates [100] . More specifically, the relative abundance of the commensal bacterial genera Lachnospira, Veillonella, Faecalibacterium, and Rothia was significantly decreased in children at risk of asthma. Furthermore, antibiotic-induced gut dysbiosis has been shown to facilitate the development of allergic asthma in experimental murine models and clinical studies [101] . In a population-based cohort, it has been reported that pre-and post-natal antibiotic exposure was associated with a higher asthma risk [102] . No significant difference in bacterial diversity was observed between samples from those with wheeze and healthy controls. Age and attendance at day care or kindergarten were important factors in driving bacterial diversity whereas wheeze and viral infection

were not found to be significantly associated to the bacterial communities. In the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort, children for whom antibiotics course was reported before the age of 2 years were more likely to have asthma at age 7, although microbiota was not characterized [103] . Similarly, in British Columbia (Canada), "controlled" antibiotic use during infancy was associated with a reduction in the incidence of pediatric asthma, and was related with the preservation of gut microbial communities [104] . Altogether, these data confirm the need to preserve the microbiota in early infancy in order to limit the development of asthma.

Bacterial infections potentially contribute to the severity of symptomatic respiratory viral infections and asthma attacks in children. Indeed, there are bidirectional interactions between viruses and airway bacteria that appear to modulate the severity of illness and the likelihood of asthma attack [20] . Pediatric studies have shown that upper respiratory tract colonization with Streptococcus, Haemophilus, and/or Staphylococcus genus during RSV and RV infection increases the risk of hospitalization independently of age and of the presence of asthma [105, 106] . In our previously-cited cohort of preschool children, asthma attacks were frequently associated with viral infection (94%, mostly RV). Pathogenic bacteria were isolated in induced sputum in 56%, mainly H. influenza, M. catharralis or S. pneumoniae [21] . In adult asthmatics, asymptomatic RV infection was associated with increased abundance of Dolosigranulum and Corynebacterium, whereas symptomatic RV infection seemed to be related with a higher frequency of Moraxella [107] . In another adult study, co-infection with virus and bacteria induced higher levels of cytokine/chemokine than bacterial infection [108] . Interestingly, circulating CCL2 and CCL5 concentrations were increased in infected asthmatic patients compared with non-asthmatic patients. Streptococcus species may also influence the course of asthma exacerbation, as shown by Kama, et al. in preschool children [109] . Indeed, patients with S. pneumoniae colonization in the pharyngeal microbiota had significantly shorter wheezing episodes and reduced lung inflammation (including lower levels of TNF-α).

In summary, these data suggest an ability for bacteria to promote asthma attacks and modulate the inflammation during childhood. Targeting bacterial infections during asthma attacks could thus be an alternative strategy in some children.

Early-life dysbiosis of the microbiota, in particular lung microbiota, may have long-term consequences on asthma natural history. During viral infection in children less than two years old, detection of Moraxella was found to be associated with current wheeze at 5 years old and presence of Streptococcus, Moraxella, or Haemophilus was associated with a high risk of asthma development [110] .

Mansbach, et al. showed in a joint modeling analysis adjusting for 16 covariates, including viral trigger, that a higher relative abundance of Moraxella or Streptococcus species 3 weeks after day 1 of hospitalization for severe bronchiolitis was associated with an increased risk of recurrent wheezing [111] . In contrast, no significant difference in microbiota composition was observed between oropharyngeal microbiota from children with acute wheezing (0-14 years old) and healthy controls [112] . In this study, the large range of patient ages and day care attendance were important confounding factors, since the microbiota evolves throughout childhood.

In school-age asthmatic children, Zhou, et al. assessed by longitudinal measurements the relationship between nasal airway microbiota and either loss of asthma control, or risk of severe exacerbations [113] . Whereas the commensal Corynebacterium / Dolosigranulum cluster characterized the patients with the lowest risk of disease progression, a switch towards the Moraxella cluster was associated with the highest risk of severe asthma exacerbations. Similarly, in another cohort of schoolage asthmatic children, nasal microbiota dominated by Moraxella species was associated with increased exacerbation risk, and eosinophil activation at exacerbation [35] . Staphylococcus or Corynebacterium species-dominated microbiota were linked with reduced respiratory illness and exacerbation event rates, whereas Streptococcus species-dominated microbiota increased the risk of RV infection.

Interestingly, using unbiased airway microbiome-driven clustering, Abdel-Aziz, et al. recently described in adult asthmatics two distinct robust severe asthma phenotypes that were associated with airway neutrophilia, and not related to the presence of Moraxella species [114] . Robinson, et al. assessed the lower airway microbiota by performing BAL at steady state in severe preschool wheezers [34] . They reported two profiles: a Moraxella species "dysbiotic" cluster, associated with airway neutrophilia and a "mixed microbiota" cluster associated with macrophage-and lymphocyte-predominant airway inflammation, thus suggesting that bacteria might influence the characteristics of lung inflammation.

Altogether, these data show that airway dysbiosis in early life might contribute to recurrent wheeze and asthma, and to the severity of the disease. Among bacterial species, the early presence of M. Catharralis and H. influenzae during childhood seems to be a marker of evolution toward a severe disease, through the modulation of the inflammatory reaction. In contract, colonization with S.

pneumoniae might have some anti-inflammatory effects. However, the role of bacteria is often exacerbated or modulated by intrinsic (atopy, inflammation characteristics) or extrinsic factors, such as viral infections and antibiotics.

It is now clear that phenotyping and even more so, endotyping asthmatic patients is an essential step to understand the diversity of immune responses at the time of an asthma attack. We will review the commonly described endotypes of childhood asthma, successively based on airway leukocyte infiltrate, profiles of allergic sensitization and nature of asthma trajectories.

Among airway inflammatory phenotypes, neutrophilic asthma appears to be a distinct endotype, associated with asthma severity in adults, and possibly involved in corticosteroid insensitivity [76] . In children, several studies have shown that association of airway neutrophilia with severity is inconstant [115] [116] [117] [118] , and may not persist throughout the course of the disease [116, 119] . However, neutrophils present in the airways of severe asthmatic children may have enhanced survival and proinflammatory functions that could increase baseline inflammation [120] . As previously stated, airway neutrophilia has also been associated with a different IFN response, at baseline and at the time of asthma attack, both in adults [66, 92] and pediatric studies [49] . This could have an impact on lung infections. Thus, we have

shown that a subgroup of school-aged children with positive viral PCR both at baseline and exacerbation displayed airway neutrophilia [49] . In severe adult asthmatics, airway neutrophilia has also been associated with lesser microbiota diversity in BAL [114, 121] . Finally, experimental RV infection in adult asthmatic subjects directly induces bronchial mucosal neutrophilia [122] . Therefore, the neutrophilic endotype may be characterized by an alteration of airway microbiota and association with viral infections.

Airway eosinophilia is highly frequent in asthmatic children, observed in severe and non-severe asthma, often but not always associated with response to ICS, thus highlighting the diversity of eosinophilic profiles in pediatric asthma [116, 118, 123] . Mouse models and adult studies have suggested a role of IL-5 induced airway eosinophilia as a positive regulator of RV receptor intercellular adhesion molecule (ICAM)-1 on AEC, and a negative regulator of PRR and antiviral responses [124, 125] .

However, in children, it remains unclear whether airway eosinophils are involved in the pathophysiology of severe asthma, and in the propensity to develop acute asthma attacks [126] . In addition, peripheral blood eosinophilia, currently used as the basis for selection of eosinophil-targeted biologics, may not be representative of airway eosinophilia in children [127] . Most importantly, it has been reported that eosinophilia is not necessarily associated with higher levels of Th2 cytokines [118] , and other cells such as alarmin-stimulated ILC2 may have a greater biological importance in the pathophysiology of asthma attacks [128] . Eosinophils can also have beneficial effects in childhood asthma, as they display regulatory functions and contribute to lung repair and mucosal homeostasis [75] . Peripheral blood eosinophilia has recently been identified has a biomarker predicting the decrease of severity throughout the adolescent years [16] . Finally, it remains to be determined whether eosinophil-targeted biologics, such as anti-IL-5 mepolizumab, are efficient in reducing asthma attacks in children [129] . Overall, as opposed to adults, airway eosinophilia does not appear as the preferential biomarker to classify pediatric patients nor to assess their risk of acute asthma attacks.

Rather than through the recruitment of eosinophils, type 2 inflammation may play a key role in some children's susceptibility to develop acute asthma attacks through IgE sensitization. Hence, atopy, defined as allergic sensitization, is a key feature associated with risk of asthma attacks in childhood [7, 8, 14] . As shown by latent-class analyses, atopy is also one of the main factors that may account for the heterogeneity of the disease, especially in the preschool years [130, 131] and could drive response to treatment [3] . Describing asthma trajectories in neonatal longitudinal cohorts may precisely allow identifying novel endotypes. For instance, in a birth cohort of children at high risk of atopy, cord blood cells were tested for their ability to produce IFN after exposure to polyinosinic-polycytidylic acid (Poly I:C), a double stranded RNA that mimics viral PAMP [137] . A group of low producers of type I and III IFN response upon stimulation representing 24% of the patients was identified. They displayed higher risk of lower respiratory tract infection and persistent wheeze at the age of 5, suggesting that these clinical outcomes are partly determined by constitutional mechanisms.

Altogether, beyond airway leukocyte and type 2 inflammation, childhood asthma endotypes seem to be associated with the characteristics of airway microbiota and of the associated immune response. Because these might involve dynamic processes, the study of asthma trajectories throughout childhood is crucial. A better characterization of asthma endotypes will be an essential step in order to achieve a personalized medicine.

Digital tools provide an innovative way to study the integrated immune response in asthmatic patients. For instance, Custovic, et al. used machine learning in an in vitro model of RV-A16 infection on PBMC extracted from 11 years old children and described 6 clusters of cytokine response to infection [138] . One cluster, with patients from whom PBMC displayed low IFN responses, high pro-inflammatory cytokines, low Th2 responses and moderate regulatory responses, was associated with early-onset asthma and the highest risk of asthma exacerbations and hospitalizations for lower respiratory tract infection.

Omic technologies, known as genomic, epigenomic, transcriptomic, proteomic, single-cell omics, metabolomics, microbiomics, exposomics, are others fast-developing tools, generating a massive amount of data reflecting the biological state of cell populations at a given time, that will certainly make possible in the future to identify new endotypes and their biomarkers [139, 140] . For instance, with the development of the Human Genome Project, genome-wide association studies have allowed to link childhood asthma with association signals in or near genes involved in innate immune response pathways, such as the TLR1 locus, and the IL-33 locus [141, 142] . Transcriptomics analyses, which aim at investigating all RNA transcripts in a biological sample, will certainly enable the identification of a large quantity of genes modulated in certain conditions. A recent study has described 94 distinct geneexpression modules between virus-induced and non-virus-induced exacerbation in nasal and sputum cells from a large cohort of school-age children [143] . In asthma attacks, this tool may also provide information on the activated pathways linked with inflammatory and anti-microbial response [144, 145] .

RNA sequencing in nasal lavage cells from asthmatic children at exacerbation led to identify some genes overexpressed as relevant "nodes" linking genes of the inflammatory response, such as IRF7 [144] .

Transcriptomic analyses have also been used to identify genes associated with different phenotypes of asthmatic patients [146] . Finally, metabolomics, the study of the metabolites produced in living systems (both humans and microbiota) represents another promising strategy in the upcoming years to address the role of immuno-metabolism as well as lung and gut microbiota in asthma pathophysiology [147, 148] .

To sum up, systemic approaches integrating all biologic pathways are now increasingly used to study the mechanisms leading to susceptibility to acute asthma attacks in children. They may facilitate the identification of novel multimodal biomarkers linked with specific endotypes and therapeutic targets.

Conventional maintenance treatment, such as ICS, may be insufficient to prevent attacks in children, especially in severe asthma. Severe therapy-resistant asthma is precisely characterized by repeated severe exacerbations despite high dose daily treatment. As the knowledge about infectionunderlying pathophysiological processes grows, new therapeutic approaches that may contribute to either improve innate immune responses or limit the occurrence and consequences of infections during asthma attacks have been recently explored (Figure 2 ).

As we have shown earlier, asthmatic children may display an impairment of PRR signaling that leads to susceptibility to infection-induced asthma attacks. One of the strategies to enhance their anti- inducing an impaired bacterial clearance [152] . We have also demonstrated in a murine model of allergic asthma that TLR3 ligands can enhance the Th2 response [153] . Thus, the exact consequences of administering exogenous TLR ligands (including TLR7-8) in humans are still unknown and their potential role in bacterial secondary infections in the lungs need to be addressed.

Another immunomodulatory strategy, particularly appealing in pediatric asthma, could rely on the administration of bacterial lysates [154] . Two following the treatment initiation, and reduced the number of acute respiratory tract illnesses [162] .

Finally, in toddlers aged 6-18 months, a clinical trial is ongoing to assess the preventive effect of OM-85V on the onset of first wheeze episode related to lower respiratory tract infection during a 3 years observational period [163] . Regarding the mechanisms of action, prevention of acute respiratory infections was not induced by purified LPS or bacterial DNA, suggesting that other PAMP contained in bacterial lysates would activate innate immunity and lead to promotion of type 1 inflammation by DC [164] [165] [166] .

Altogether, immunostimulatory therapeutics may represent a promising strategy as additional treatments to prevent asthma attacks but their safety and efficacy need to be properly addressed.

Because multiple microorganisms may be involved in acute asthma, it remains also unclear whether they would have an impact on the onset and severity of acute asthma attacks in children.

Anti-microbial peptides, among which LL-37, are key molecules of the innate immune responses against both viruses and bacteria. Thus, it has been hypothesized that supplementing with LL-37 or inducing its production among AEC could enhance anti-infectious defenses. Sousa, et al. have tested the effect of exogenous cathelicidin on RV-1B replication after inoculation on cultures of AEC [167] .

They reported that exogenous LL-37, as well as homologous porcine cathelicidins, either administered prior or after infection, displayed antiviral activity against RV by reducing the metabolic activity of infected cells. However, one preclinical study in a mouse model of asthma showed in vivo a deleterious effect of exogenous cathelicidin-related antimicrobial peptide in airway inflammation and responsiveness [168] , and to our knowledge, there is no published study in vivo in humans. Nevertheless, promising results regarding vitamin D supplementation on the release of LL-37 by AEC in in vitro experiments have been published [169] [170] [171] . In clinical studies, there is evidence toward a protective effect of vitamin D supplementation on risk of acute respiratory infections in children [172] . Although there are other effects of vitamin D that might explain its clinical efficacy [80, 173] , there is a well-studied biological link between vitamin D and host microbial peptides, via the translocation of vitamin D to the nucleus of AEC, where it activates Vitamin v responsive elements in promoter regions of anti-microbial peptide genes such as LL-37 [52, 171, 174] . Hence, targeting the vitamin D / cathelicidin axis could represent a promising strategy during acute asthma in children.

As studies have shown deficient IFN responses in asthmatic patients, it has been hypothesized that IFN supplementation upon viral infection could enhance anti-viral responses and reduce asthma attacks severity. Interferon therapies (pegylated IFN-α in association with ribavirin) have first been developed in other diseases such as in hepatitis C and human immunodeficiency virus [175, 176] .

Ribavirin is a synthetic guanosine nucleoside that impairs the synthesis of viral mRNA [52] . Its clinical utility, upon respiratory virus infection, has been shown in RSV, Adenovirus, RV, or in (SARS)-CoV immunocompromised patients [177] [178] [179] [180] . Since exogenous IFNs reduced RV replication in in vitro cultures of RV-infected AEC from asthmatic patients [181] , a trial was initiated in 147 adult asthmatic patients developing symptoms of viral infection (68% RV) to evaluate the efficacy of inhaled IFN-β treatment for 14 days [182] . Overall, it did not improve asthma symptoms, but it enhanced morning peak expiratory flow recovery and reduced the need for additional treatment, i.e. oral corticosteroids or antibiotics. In an exploratory analysis of the subset of more difficult-to-treat patients, IFN supplementation improved asthma control questionnaires. In addition, it boosted anti-viral innate immunity with persistent elevated serum levels of CXCL10, and decreased levels of pro-inflammatory molecules such as CCL4 and CXCL8. In the INEXAS phase 2 trial, designed to assess efficacy of inhaled IFN-β1a for 14 days to prevent asthma exacerbations in adults, McCrae, et al. also reported improvement in the morning peak expiratory flow in the treated arm compared with placebo, but the study stopped early [183, 184] . No study has yet been conducted in pediatric patients.

Collectively, anti-viral therapies could represent potential therapies in the treatment of acute asthma attacks in children. However, the exact timing of administration upon viral infection and onset of acute asthma, and the population of children who might benefit from these strategies remain to be determined.

Apart from ribavirin, other anti-viral therapies, such as capside-targeting molecules pleconaril, BTA-798 and V-073 have been studied in enteroviruses infections. However, none of these compounds have proven sufficient efficacy and safety in clinical trials [185] . In particular, a phase 2 clinical trial with intranasal pleconaril in children aged 6 years and older, and adults, showed no impact of treatment on the onset of RV-induced cold symptoms or acute asthma exacerbation [186] . Although their efficacy needs to be addressed in clinical trials, DNAzyme therapies could also be promising strategies, as recently suggested by an in vitro study showing good catalytic activity of 2 candidates (Dua-01 and Dua-02) on various RV strains [187] .

As described above, bacteria and microbiota may be associated with asthma development and attacks, and antibacterial therapies have emerged as alternative strategies to prevent and/or to treat asthma exacerbation [154, 188, 189] . Treatments aiming to influence the composition of the microbiota are presently tested in different clinical situations and recent data have suggested that these methods might have some interest in asthma. Transplantation of healthy microbiota seems a promising alternative as demonstrated in gut inflammatory diseases [190] . In preclinical study, Arrieta, et al. demonstrated that oral inoculation with four bacterial species previously identified as associated with risk of childhood asthma to germ-free mice improved allergic airway inflammation in their adult offspring [100] . Several studies have also evaluated the benefit of prebiotic and probiotic but their interest during childhood asthma attack has yet to be evaluated [191, 192] . Another option may be to administer bacteria metabolites, which can mimic the effect of normal microbiota. Thus, feeding pregnant mice with short chain fatty acid (SCFA), such as acetate, was associated with modulation of the maternal microbiota and protection from developing allergic airway disease in the offspring [193] . Finally, an increasing number of studies in experimental models of lung infections has demonstrated the potential interest of fecal microbiota transplantation and/or SCFA supplementation, suggesting that they might be efficient in bacteria-and virus-induced exacerbations [194] [195] [196] .

The potential modulatory effects of some antibiotics on asthma attacks in children are subject of intense research. First, in terms of prevention, Schwerk, et al. observed a positive impact of long-term antibiotics (mainly amoxicillin and amoxicillin-clavulanic acid) in preschoolers with severe wheeze who had positive bacterial infection on BAL samples, with reduced rates of exacerbations and hospitalizations at 6 months follow-up compared with rates before treatment [197] . Second, immunomodulatory effects of macrolides are well-described [198] , limited evidence on the use of azithromycin as a preventive treatment of acute asthma attacks [202] . In addition, studies have been conducted in adult patients to test the effect of azithromycin as a preventive strategy, with conflicting results [203] [204] [205] . Notably, Gibson, et al. described in a placebo-controlled trial that 48 weeks maintenance treatment with azithromycin decreased the frequency of asthma exacerbations and improved asthma-related quality of life in symptomatic asthma despite current maintenance treatment [204] . In a meta-analysis of the three main studies conducted in adult patients [203] [204] [205] , maintenance treatment with azithromycin was associated with a reduced rate of exacerbations in asthma as well as in all subgroups (non-eosinophilic, eosinophilic and severe asthma), and a good tolerance [206] . Examining each exacerbation type separately, patients with eosinophilic asthma reported fewer oral corticosteroid courses, and patients with non-eosinophilic and severe asthma reported fewer antibiotic courses. Additionally, a specific effect of macrolides in neutrophilic asthma had been reported previously by Simpson, et al. in adult subjects with severe refractory asthma, treated with clarithromycin for 8 weeks [207] . Clarithromycin therapy reduced sputum concentrations of IL-8 and neutrophil numbers leading to lower levels of neutrophil elastase and Matrix metallopeptidase (MMP)-9 concentrations versus placebo. Finally, a decrease of inflammatory cytokines, notably IL-1β, IL-6 and IL-33, was observed in vitro in cultures of human AEC from asthmatic patients pretreated with clarithromycin, in a context of RV14 infection, suggesting a direct anti-viral effect [208] . Consistent with this hypothesis, another in vitro study showed an effect of azithromycin to reduce RV replication after inoculation in AEC, associated with an increase in IFN and interferon-stimulated genes mRNA expression and protein production [209] .

To sum up, although macrolides and more particularly azithromycin constitute an appealing strategy in acute asthma, further studies are needed to identify the phenotypes of potential responders and the possible adverse events. Since antibiotics have the potential limitation of eliminating commensal bacteria that protect from asthma development, it must be emphasized that their use should only be considered in particular clinical situations [188] .

We have highlighted the close interactions between underlying airway inflammation, host antimicrobial responses and microorganisms leading to asthma attacks. Therefore, novel therapeutics targeting inflammatory pathways in asthma, such as anti-Th2 inflammation biologics, may have a specific impact on lung infections.

Omalizumab is an anti-IgE monoclonal antibody, targeting the effector mechanisms of Th2 inflammation. After proof of efficacy in pediatric clinical trials, it has been widely prescribed in severe asthmatic atopic children aged older than 6 years, providing more insights on the longer-term evolution [210] . In real-life studies, we have observed higher levels of asthma control after its initiation, and a significant decrease of asthma attacks in children previously prone to exacerbation [211] . Hence, a direct effect of omalizumab on RV-induced exacerbations in children has been suggested [212, 213] shedding, and risk of RV-induced illnesses in omalizumab-treated patients [212] . A recently published adult study including results from two clinical trials has compared the effect of omalizumab on the response to an experimental inoculation with RV-16 in allergic asthmatic adults [214] . Omalizumabtreated patients displayed a reduction of symptoms of lower respiratory tract infection, more pronounced in the four first days following inoculation, suggesting that the protective effect of omalizumab on virusinduced exacerbations occurs in the early stages of infection. Teach, et al. described other results from the PROSE study that compared omalizumab with placebo and omalizumab with an inhaled corticosteroid boost with regard to fall exacerbation rates when initiated 4 to 6 weeks before return to school [215] . They recorded 86 exacerbations, among which 89% were associated with a respiratory tract virus detection, most commonly RV (81%). More importantly, they observed a significantly lower fall exacerbation rate in the omalizumab group, but no difference between omalizumab and inhaled corticosteroid boost except in the subgroup of patients with exacerbation during the run-in phase. In an ex vivo study of PBMC taken during the intervention phase, the authors observed increased IFN-α responses following RV-A16 inoculation in the omalizumab-treated group, suggesting that the mechanism of Omalizumab protection against exacerbations could involve IFN-α dependent antiviral effect [20] . Another study in children with exacerbation-prone asthma before and during omalizumab treatment described the effect of ex vivo inoculation of RV and Influenza A virus on PBMC and blood pDC, after IgE cross-linking on cell-surface FcεRI [216] . The authors observed that omalizumab increased both virus-induced IFN-α responses in PBMCs and pDC, and subsequently reduced FcεRI expression on pDC. Altogether, the lower asthma exacerbation rates consecutive to omalizumab treatment were related to IFN-α responses and attenuated FcεRI expression on pDC.

Omalizumab remains the most-studied biologic in pediatric asthma but others have been experimented in the past years [217] . Mepolizumab, an anti-IL-5 antibody therapy, has proven to be efficient in reducing the exacerbation rate in adults and is now available in children older than 6 years old with eosinophilic asthma in Europe and the US [218] . As previously stated, its efficacy in reducing exacerbation rates in pediatric clinical trials and real-life studies remain to be determined [129] .

However, adult studies suggest it may have a modifying effect on RV-induced inflammatory response.

Hence, a placebo-controlled trial was conducted in adult patients with mild asthma, randomized to receive mepolizumab versus placebo, followed by RV-16 inoculation, to study its impact on anti-viral responses [219] . The authors showed that mepolizumab attenuated baseline blood eosinophils numbers and activation status, but did not prevent the activation of remaining eosinophils upon RV infection.

However, after infection, it enhanced levels of airway B lymphocytes and AM and modified BAL levels of CCL20 and IL-1RA. Effects of other drugs targeting Th2 cytokines and alarmins, including lebrikizumab (anti IL-13), dupilumab (anti IL-4R), reslizumab (anti-IL-5), benralizumab (anti-IL-5R), tezepelumab (anti-TSLP), or anti-IL-33 monoclonal antibodies are currently studied in pre-clinical and clinical studies [217] .

In the next years, new studies are needed regarding these novel treatments, both in allergic and non-allergic asthmatic children, to provide new evidence on their immunological effects and potential disease-modifying properties, and to fully determine the phenotypes/endotypes of good responders.

Most importantly, specific studies in the youngest children need to be carried out, with appropriate endpoints [129] . This effort will contribute to enter the era of precision medicine in pediatric asthma.

In conclusion, asthma attacks are a main feature of pediatric asthma, especially of severe asthma. We have highlighted studies suggesting impairment of the mucosal anti-microbial immune responses during acute asthma and/or at steady state. Interestingly, these alterations seem to inconstantly persist into adulthood. These various altered pathways may reflect different endotypes underlying asthma heterogeneity and consequently, constitute targets for new treatment approaches.

Preventing, understanding and efficiently managing acute asthma attacks remain one of the unmet needs in severe childhood asthma, especially in the youngest children. At the era of precision medicine, early interventions targeting mucosal immune responses, lung infections, and microbiota, in early childhood, could have disease-modifying properties and positive impact on the trajectory of childhood asthma.

Characteristics of host-microbiota interactions in asthmatic children favor asthma attacks and may allow to define asthma endotypes. This knowledge offers promising perspectives to treat asthmatic children using precision medicine. 

Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries

Advances in the aetiology, management, and prevention of acute asthma attacks in children

Exacerbation risk and characterisation of the UK's asthma population from infants to old age

Report: Global strategy for asthma management and prevention

Classification and pharmacological treatment of preschool wheezing: changes since

Childhood Asthma Research and Education Network, National Heart, Lung, and Blood Institute, Severe intermittent wheezing in preschool children: a distinct phenotype

Severe preschool asthmatics have altered cytokine and anti-viral responses during exacerbation

Community study of role of viral infections in exacerbations of asthma in 9-11 year old children

Rhinovirus and asthma: reinfection, not persistence

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

Problematic Severe Asthma in Childhood Initiative group, Problematic severe asthma in children, not one problem but many: a GA2LEN initiative

Baseline Features of the Severe Asthma Research Program (SARP III) Cohort: Differences with Age

The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts

Exacerbation-Prone Asthma

Severe asthma during childhood and adolescence: A longitudinal study

Trajectories of lung function during childhood

Management of Preschool Children with Recurrent Wheezing: Lessons from the NHLBI's Asthma Research Networks

How can we minimise the use of regular oral corticosteroids in asthma?

Immunomodulation in Pediatric Asthma, Front Pediatr

Role of viral infections in the development and exacerbation of asthma in children

Rhinovirus-induced bronchiolitis and asthma development

Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children

Rhinovirusinduced first wheezing episode predicts atopic but not nonatopic asthma at school age

Post-bronchiolitis Use of Asthma Medication: A Prospective 1-year Follow-up Study

Early life rhinovirus wheezing, allergic sensitization, and asthma risk at adolescence

Role of viruses and atypical bacteria in exacerbations of asthma in hospitalized children: a prospective study in the Nord-Pas de Calais region (France)

Prevalence of viral respiratory tract infections in children with asthma

Comparison of viral load in individuals with and without asthma during infections with rhinovirus

IFN-α/IFN-λ responses to respiratory viruses in paediatric asthma

Microbiological status in preschool asthma: the VIRASTHMA 2 study

Childhood asthma after bacterial colonization of the airway in neonates

Detection of pathogenic bacteria during rhinovirus infection is associated with increased respiratory symptoms and asthma exacerbations

Lower airway microbiota associates with inflammatory phenotype in severe preschool wheeze

National Institute of Allergy and Infectious Diseases-sponsored Inner-City Asthma Consortium, Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma

The airway epithelium: soldier in the fight against respiratory viruses

Cytokines and Chemokines as Biomarkers of Future Asthma, Front Pediatr

The Interplay between Host Immunity and Respiratory Viral Infection in Asthma Exacerbation

Respiratory epithelial cells orchestrate pulmonary innate immunity

Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens

Plasmacytoid dendritic cells: in search of their niche in immune responses

Innate immune response to viral infection of the lungs

Dendritic cells and toll-like receptors in allergy and asthma

The nature of the principal type 1 interferon-producing cells in human blood

Impaired innate interferon induction in severe therapy resistant atopic asthmatic children

TLR3 and MDA5 signalling, although not expression, is impaired in asthmatic epithelial cells in response to rhinovirus infection

Toll-like Receptor 7 Is Reduced in Severe Asthma and Linked to an Altered MicroRNA Profile

Rhinovirus 16-induced IFN-α and IFN-β are deficient in bronchoalveolar lavage cells in asthmatic patients

Virus-triggered exacerbation in allergic asthmatic children: neutrophilic airway inflammation and alteration of virus sensors characterize a subgroup of patients

Relationship between immune parameters during a severe exacerbation in allergic asthmatic children and asthma outcomes in the following year

The role of viruses in acute exacerbations of asthma

Antiviral therapeutic approaches for human rhinovirus infections

Antiviral potential of cathelicidins

Cathelicidins Have Direct Antiviral Activity against Respiratory Syncytial Virus In Vitro and Protective Function In Vivo in Mice and Humans

The association of vitamin D, cathelicidin, and vitamin D binding protein with acute asthma attacks in children

Deficient antiviral immune responses in childhood: distinct roles of atopy and asthma

Increased nuclear suppressor of cytokine signaling 1 in asthmatic bronchial epithelium suppresses rhinovirus induction of innate interferons

Impaired airway epithelial cell responses from children with asthma to rhinoviral infection

Th2 cytokines impair innate immune responses to rhinovirus in respiratory epithelial cells

Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus

Innate Immune Response to Viral Infections in Primary Bronchial Epithelial Cells is Modified by the Atopic Status of Asthmatic Patients

Atopic phenotype in children is associated with decreased virus-induced interferon-alpha release

Impaired virusinduced interferon-alpha2 release in adult asthmatic patients

Peripheral blood mononuclear cells from patients with bronchial asthma show impaired innate immune responses to rhinovirus in vitro

Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children

Reduced Antiviral Interferon Production in Poorly Controlled Asthma Is Associated With Neutrophilic Inflammation and High-Dose Inhaled Corticosteroids

Bronchial mucosal IFN-α/β and pattern recognition receptor expression in patients with experimental rhinovirus-induced asthma exacerbations

Interferon gene expression in sputum cells correlates with the Asthma Index Score during virus-induced exacerbations

IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex

A mechanistic role for type III IFN-λ1 in asthma exacerbations mediated by human rhinoviruses

Role of deficient type III interferon-lambda production in asthma exacerbations

Immunologic mechanisms in asthma

Epithelial-Derived Cytokines in Asthma

Pathological Roles of Neutrophil-Mediated Inflammation in Asthma and Its Potential for Therapy as a Target

Eosinophils in mucosal immune responses

IL-17 in severe asthma. Where do we stand?

IL-13, and IL-17A differentially affect the profibrotic and proinflammatory functions of fibrocytes from asthmatic patients

Clinical and Th1/Th2 immune response features of hospitalized children with human rhinovirus infection

Thymic stromal lymphopoietin is induced by respiratory syncytial virus-infected airway epithelial cells and promotes a type 2 response to infection

Soluble ST2 regulation by rhinovirus and 25(OH)-vitamin D3 in the blood of asthmatic children

IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo

Interleukin 33 Selectively Augments Rhinovirus-Induced Type 2 Immune Responses in Asthmatic but not Healthy People, Front Immunol

Activation of lymphocytes induced by bronchial epithelial cells with prolonged RSV infection

Interferon response factor 3 is essential for house dust mite-induced airway allergy

Association between human rhinovirus C and severity of acute asthma in children

Cadherin-related family member 3, a childhood asthma susceptibility gene product, mediates rhinovirus C binding and replication

Effects of rhinovirus species on viral replication and cytokine production

Nasal Cytokine Profiles of Patients Hospitalised with Respiratory Wheeze Associated with Rhinovirus C, Viruses

Rhinovirus Viremia in Patients Hospitalized With Community-Acquired Pneumonia

Prospective evaluation of rhinovirus infection in healthy young children

Duration of rhinovirus shedding in the upper respiratory tract in the first year of life

Raised interferon-β, type 3 interferon and interferon-stimulated genes -evidence of innate immune activation in neutrophilic asthma

The Virome of the Human Respiratory Tract

Metagenomic analysis of viral genetic diversity in respiratory samples from children with severe acute respiratory infection in China

The Virome and Its Major Component, Anellovirus, a Convoluted System Molding Human Immune Defenses and Possibly Affecting the Development of Asthma and Respiratory Diseases in Childhood, Front Microbiol

Associations between nasal torquetenovirus load and spirometric indices in children with asthma

Role of the Airway Microbiome in Respiratory Infections and Asthma in Children

The Role of the Microbiome in the Developmental Origins of Health and Disease

Children with asthma by school age display aberrant immune responses to pathogenic airway bacteria as infants

Early infancy microbial and metabolic alterations affect risk of childhood asthma

Dysbiosis of the gut and lung microbiome has a role in asthma

Prenatal antibiotic exposure and childhood asthma: a population-based study

Antibiotic exposure in the first two years of life and development of asthma and other allergic diseases by 7.5 yr: a dosedependent relationship

Decreasing antibiotic use, the gut microbiota, and asthma incidence in children: evidence from population-based and prospective cohort studies

Host Transcriptome, and Disease Severity in Children with Respiratory Syncytial Virus Infection

Respiratory syncytial virus and rhinovirus severe bronchiolitis are associated with distinct nasopharyngeal microbiota

Community-acquired rhinovirus infection is associated with changes in the airway microbiome

Increased Systemic Cytokine/Chemokine Expression in Asthmatic and Non-asthmatic Patients with Bacterial, Viral or Mixed Lung Infection

The Suppressive Role of Streptococcus pneumoniae Colonization in Acute Exacerbations of Childhood Bronchial Asthma

Airway Microbiota Dynamics Uncover a Critical Window for Interplay of Pathogenic Bacteria and Allergy in Childhood Respiratory Disease

Increased Moraxella and Streptococcus species abundance after severe bronchiolitis is associated with recurrent wheezing

Viral respiratory infections and the oropharyngeal bacterial microbiota in acutely wheezing children

The upper-airway microbiota and loss of asthma control among asthmatic children

Sputum microbiome profiles identify severe asthma phenotypes of relative stability at 12-18 months

Assessment of airway inflammation and remodeling in children with severe asthma: The next challenge

Remodelling and inflammation in preschoolers with severe recurrent wheeze and asthma outcome at school age

Neutrophilic Inflammation in Asthma and Association with Disease Severity

Pediatric severe asthma is characterized by eosinophilia and remodeling without T(H)2 cytokines

Sputum inflammatory phenotypes are not stable in children with asthma

Children with Neutrophil-Predominant Severe Asthma Have Proinflammatory Neutrophils With Enhanced Survival and Impaired Clearance

Inflammatory phenotypes in patients with severe asthma are associated with distinct airway microbiology

Airway inflammation and illness severity in response to experimental rhinovirus infection in asthma

Neutrophilic Steroid-Refractory Recurrent Wheeze and Eosinophilic Steroid-Refractory Asthma in Children

Involvement and Possible Role of Eosinophils in Asthma Exacerbation

Toll-like receptor 7 governs interferon and inflammatory responses to rhinovirus and is suppressed by IL-5-induced lung eosinophilia

Use of sputum eosinophil counts to guide management in children with severe asthma

Blood Eosinophilia May Not Adequately Estimate Lung Fluid Eosinophilia in Childhood Asthma

Pulmonary type-2 innate lymphoid cells in paediatric severe asthma: phenotype and response to steroids

Biologics for paediatric severe asthma: trick or TREAT?

Novel severe wheezy young children phenotypes: boys atopic multiple-trigger and girls nonatopic uncontrolled wheeze

NIAID sponsored Inner-City Asthma Consortium, Longitudinal Phenotypes of Respiratory Health in a High-Risk Urban Birth Cohort

Interactions between Innate Antiviral and Atopic Immunoinflammatory Pathways Precipitate and Sustain Asthma Exacerbations in Children

Evolution pathways of IgE responses to grass and mite allergens throughout childhood

Multicentre Allergy Study (MAS) group, Perennial allergen sensitisation early in life and chronic asthma in children: a birth cohort study

Early polysensitization is associated with allergic multimorbidity in PARIS birth cohort infants

MAS, PASTURE study groups, Latent class analysis reveals clinically relevant atopy phenotypes in 2 birth cohorts

Developmental regulation of type 1 and type 3 interferon production and risk for infant infections and asthma development

Cytokine Responses to Rhinovirus and Development of Asthma, Allergic Sensitization, and Respiratory Infections during Childhood

The current state of omics technologies in the clinical management of asthma and allergic diseases

The use of pharmacogenomics, epigenomics, and transcriptomics to improve childhood asthma management: Where do we stand?

Genetic risk factors for the development of pulmonary disease identified by genome-wide association

A large-scale, consortium-based genomewide association study of asthma

Transcriptome networks identify mechanisms of viral and nonviral asthma exacerbations in children

Interferon regulatory factor 7 is a major hub connecting interferon-mediated responses in virus-induced asthma exacerbations in vivo

Expression profiling of genes related to asthma exacerbations

Transcriptome analysis of controlled and therapy-resistant childhood asthma reveals distinct gene expression profiles

Children with severe asthma have unique oxidative stress-associated metabolomic profiles

Gut microbial-derived butyrate is inversely associated with IgE responses to allergens in childhood asthma

Down modulation of human TLR3 function by a monoclonal antibody

Toll-like receptor 3 blockade in rhinovirus-induced experimental asthma exacerbations: A randomized controlled study

Activation of toll-like receptor signaling pathway for protection against influenza virus infection

Poly I:C enhances susceptibility to secondary pulmonary infections by gram-positive bacteria

Double-stranded RNA exacerbates pulmonary allergic reaction through TLR3: implication of airway epithelium and dendritic cells

Emerging Therapies in the Treatment of Early Childhood Wheeze

Polyvalent mechanical bacterial lysate for the prevention of recurrent respiratory infections: a meta-analysis

Safety and Efficacy of Two Courses of OM-85 BV in the Prevention of Respiratory Tract Infections in Children During 12 Months

OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review

Stimulation of nonspecific immunity to reduce the risk of recurrent infections in children attending day-care centers. The Epicrèche Research Group

Broncho-Vaxom in pediatric recurrent respiratory tract infections: A systematic review and meta-analysis

The administration of a polyvalent mechanical bacterial lysate in elderly patients with COPD results in serological signs of an efficient immune response associated with a reduced number of acute episodes

Mechanical bacterial lysate administration prevents exacerbation in allergic asthmatic children-The EOLIA study

The immunostimulant OM-85 BV prevents wheezing attacks in preschool children

Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness -Full Text View -ClinicalTrials.gov

Th1-orientated immunological properties of the bacterial extract OM-85-BV

A clinically approved oral vaccine against pneumotropic bacteria induces the terminal maturation of CD83+ immunostimulatory dendritic cells

Stimulation of Immunoprotective Mechanisms by OM-85 BV

Cathelicidins display conserved direct antiviral activity towards rhinovirus

Exogenous murine antimicrobial peptide CRAMP significantly exacerbates Ovalbumin-induced airway inflammation but ameliorates oxazolone-induced intestinal colitis in BALB/c mice

Vitamin D increases the antiviral activity of bronchial epithelial cells in vitro

Vitamin D attenuates rhinovirus-induced expression of intercellular adhesion molecule-1 (ICAM-1) and platelet-activating factor receptor (PAFR) in respiratory epithelial cells

Vitamin D represses rhinovirus replication in cystic fibrosis cells by inducing LL-37

Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and metaanalysis of individual participant data

The role of vitamin D in asthma

Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression

Pegylated interferon alfa for chronic hepatitis B: systematic review and meta-analysis

Interferon Alpha Subtype-Specific Suppression of HIV-1 Infection In Vivo

Comparative effectiveness of aerosolized versus oral ribavirin for the treatment of respiratory syncytial virus infections: A single-center retrospective cohort study and review of the literature

Update in the treatment of non-influenza respiratory virus infection in solid organ transplant recipients

Treatment of persistent rhinovirus infection with pegylated interferon α2a and ribavirin in patients with hypogammaglobulinemia

The management of coronavirus infections with particular reference to SARS

Effect of exogenous interferons on rhinovirus replication and airway inflammatory responses

The effect of inhaled IFN-β on worsening of asthma symptoms caused by viral infections. A randomized trial

On-Demand Inhaled Interferon-Beta 1a for the Prevention of Severa Asthma Exacerbations: Results of the INEXAS Phase 2a Study

A Study in Asthma Patients to Evaluate Efficacy, Safety and Tolerability of 14 Days Once Daily Inhaled Interferon Beta-1a After the Onset of Symptoms of an Upper Respiratory Tract Infection -Full Text View -ClinicalTrials

Combating enterovirus replication: state-of-theart on antiviral research

Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure (Study P04295) -Study Results -ClinicalTrials.gov

Development and characterization of DNAzyme candidates demonstrating significant efficiency against human rhinoviruses

Azithromycin is the answer in paediatric respiratory medicine, but what was the question?

Question 4: Is there a role for antibiotics in infantile wheeze?

Timing for the second fecal microbiota transplantation to maintain the long-term benefit from the first treatment for Crohn's disease

The Role of Probiotics in Preventing Allergic Disease

Prebiotics for the prevention of allergies: A systematic review and meta-analysis of randomized controlled trials

Evidence that asthma is a developmental origin disease influenced by maternal diet and bacterial metabolites

The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia

Gut Dysbiosis during Influenza Contributes to Pulmonary Pneumococcal Superinfection through Altered Short-Chain Fatty Acid Production

The microbiota protects against respiratory infection via GM-CSF signaling

Wheeze in preschool age is associated with pulmonary bacterial infection and resolves after antibiotic therapy

The Immunomodulatory Effects of Macrolides-A Systematic Review of the Underlying Mechanisms

Early Administration of Azithromycin and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool Children With a History of Such Illnesses: A Randomized Clinical Trial

Azithromycin for episodes with asthma-like symptoms in young children aged 1-3 years: a randomised, double-blind, placebo-controlled trial

Treatment of preschool children presenting to the emergency department with wheeze with azithromycin: A placebocontrolled randomized trial

Efficacy of Macrolides on Acute Asthma or Wheezing Exacerbations in Children with Recurrent Wheezing: A Systematic Review and Meta-analysis

Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised doubleblind placebo-controlled trial

Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial

AZMATICS (AZithroMycin-Asthma Trial In Community Settings) Study Group, Azithromycin for bronchial asthma in adults: an effectiveness trial

Does maintenance azithromycin reduce asthma exacerbations? An individual participant data meta-analysis

Clarithromycin targets neutrophilic airway inflammation in refractory asthma

Clarithromycin decreases rhinovirus replication and cytokine production in nasal epithelial cells from subjects with bronchial asthma: effects on IL-6, IL-8 and IL-33

Azithromycin induces anti-viral responses in bronchial epithelial cells

Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children

Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey

Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma

Omalizumab Is Associated with Reduced Acute Severity of Rhinovirus-triggered Asthma Exacerbation

Understanding the Asthmatic Response to an Experimental Rhinovirus Infection: Exploring the Effects of Blocking IgE

Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations

Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab

New perspectives of childhood asthma treatment with biologics

Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype

Anti-IL-5 in Mild Asthma Alters Rhinovirus-induced Macrophage, B-Cell, and Neutrophil Responses (MATERIAL). A Placebo-controlled, Double-Blind Study

Our studies received grant supports from the "Conseil regional des hauts de France " (Virasthma 1 and Virasthma 2), the Société Française d'Allergologie, and the « Comité National contre les maladies respiratoires » (Virasthma 1), the « Fondation du souffle » and Stallergen greer (Virasthma 2) . Our research is also supported by INSERM, CNRS and University of Lille. 

PIV-3 / RV-B1 Adults: atopic asthma / non-atopic asthma / healthy controls Atopic asthma: After PIV3 infection: higher IFN-λ1, IFN-α, IFN-β and IRF7 expressions After RV1B infection: IFN-β higher than in non-atopic asthmatics

Rupani H, et al. 2016 [47] RV-A16 Pre-treatment with Imiquimod (TLR7 agonist) Adults: severe asthma / Healthy controls In severe asthma: reduced TLR7 expression, inverse correlation with number of exacerbations Increased levels of 3 microRNAs (miR-150, miR-152, and miR-375) Restored TLR7 expression after blocking these microRNAs with anti-miRNA oligonucleotides

Sykes A, et al. 2012 [48] RV-A16 Adults: mild-to-moderate allergic asthma vs healthy controls This reduction in bacterial taxa was accompanied by reduced levels of fecal acetate. Inoculation of germ-free mice with these four bacterial taxa ameliorated airway inflammation in their adult progeny.

213, 661 mother-child dyads with a median follow-up time of 9.3 years from birth Maternal antibiotic use was determined from records of oral antibiotic prescriptions 36.8% of children were exposed prenatally to antibiotics and 10.1% developed asthma. Prenatal antibiotic exposure was associated with an increased risk of asthma.Maternal antibiotic use during 9 months before pregnancy and 9 months postpartum were similarly associated with asthma.

4,952 children from the Avon Longitudinal Study of Parents and Children (ALSPAC). Child antibiotic use and asthma, eczema and hay fever symptoms were reported Children reported to have taken antibiotics during infancy (0-2 yr) were more likely to have asthma. The risk increased with greater numbers of antibiotic courses. The number of courses was also associated with a higher risk of eczema and hay fever but not atopy.

2,644 children from the Canadian Healthy Infant Longitudinal Development (CHILD) prospective birth cohort and among them, 917 were analyzed for fecal microbiota Reduction in asthma incidence over the study period was associated with decreasing antibiotic use in the first year of life. Asthma diagnosis in childhood was associated with infant antibiotic use (adjusted odds ratio [aOR] 2.15), with a significant dose-response; α-diversity of the gut microbiota was associated with a 32% reduced risk of asthma at age 5 years.

The [114] Sputum samples were collected in 100 severe asthmatics of the U-BIOPRED adult patients cohort at baseline and after 12-18 months of follow-up Two microbiome-driven clusters were identified, characterized by asthma onset, smoking status, treatment, lung spirometry results, percentage of neutrophils and macrophages in sputum.Patients of the most severe cluster displayed a commensal-deficient bacterial profile which was associated with worse asthma outcomes. Longitudinal clusters revealed high relative stability after 12-18 months in the severe asthmatics.

Robinson PFM, et al. 2019 [34] Children: 35 wheezers categorized as MTW or EVW BAL obtained at steady state There was no relationship between lower airway inflammation or infection and clinical preschool wheeze phenotypes. 2 groups identified: 1) a Moraxella species dysbiotic microbiota cluster that associated with airway neutrophilia and a mixed microbiota; 2) a mixed microbiota cluster with a macrophage-and lymphocytepredominant inflammatory profile